

Renal failure related to fibrates administration (n = 46)[☆]

Insuficiencia renal asociada al uso de fibratos (n = 46)

Dear Editor,

Hyperlipidaemia is a widespread health problem in the general population; it needs to be treated to achieve a reduction of cardiovascular risk factors and therefore morbidity and mortality,¹ this consideration is more important in renal patients, as they already present a high cardiovascular risk.² Thus, in these patients, the use of fibrates to control hypertriglyceridemia is common,³ but this can lead to additional problems; it is well known the relationship between the use of fibrates and impaired kidney function.^{1,3} We collected 46 cases of kidney failure, associated with treatment with fenofibrate, that occurred at our centre and in which the impaired kidney function could only be attributed to the initiation of treatment with this drug. Changes in kidney function before and after starting the drug, and after its withdrawal were analysed. Changes in proteinuria after discontinuation of the drug were also documented. All patients had chronic kidney disease (CKD) stages II-IV. There were 71.7% of men and 84.8% were receiving drugs that block the renin-angiotensin-aldosterone

system (RAAS) and 73.9% were on statins. Mean treatment time was 30.7 months (± 24.31), and the mean dose was 159.3 mg (± 22.64). There were 67.4% diabetics and 91.3% hypertensive (Table 1). Mean plasma creatinine (Cr) increased from 1.4 mg/dl (± 0.37) to 2.0 mg/dl (± 0.48), after starting fibrates. Two months after discontinuation of the drug the serum Cr decreased to 1.4 mg/dl (± 0.33). This value of Cr was maintained over 12 months, with mean of 1.4 mg/dl (± 0.42) (Table 2). Glomerular filtration rate (GFR), estimated by the CKD-EPI equation, increased from 33.6 ml/min (± 10.17), when the drug was discontinued, to 51.3 ml/min (± 19.22) a year after it was stopped. Two months after discontinuation of the drug the albumin/creatinine ratio (ACR) increased from 338 mg/g (± 774) to 893 mg/g; but, after 12 months this initial increase disappeared, and the urine ACR was 309 mg/g (± 676). Cases in which the impaired kidney function could have been related to other nephrotoxic agents or associated factors, that could reduce GFR were excluded; and, it became evident that there was a clear temporal relationship between impaired kidney function and the initiation of treatment with fenofibrate, as well as recovery after stopping fenofibrate.³ This association has been describe in the literature^{4,5} in patients with normal kidney function and in those with kidney failure, but the present incidence is not known.⁶ As a pathophysiological mechanism, it has been linked to a decreased production of vasodilator prostaglandins and a possible natriuretic effect that might cause vasoconstriction of the afferent arteriole and RAAS activation.^{1,7} Of the cases collected, 84% were receiving RAAS-blocking drugs. It has been reported that kidney failure associated with the use of fibrates is more common when drugs that affect renal haemodynamics are used simultaneously.^{4,7} Other proposed reason for the elevation of blood creatinine is increased creatinine production due to

Table 1 – Characteristics of the population studied.

| | |
|------------------------|-----------------------|
| Age (years) | 70.3 (± 9.99) |
| Time (months) | 30.7 (± 24.31) |
| Dose (mg) | 159.3 (± 22.64) |
| Gender (% men/% women) | 71.7/38.3 |
| DM (%) | 67.4 |
| HTN (%) | 91.3 |
| RAASB (%) | 84 |
| Statins (%) | 75 |

RAASB: renin-angiotensin-aldosterone system blockers; DM: diabetes mellitus; HTN: hypertension.

Table 2 – Evolution of serum creatinine, glomerular filtration rate (CKD-EPI) and proteinuria in relation to the initiation and discontinuation of fenofibrate.

| Variable | Before fibrate | With fibrate | Two months after discontinuation of fibrate | Twelve months after discontinuation of fibrate |
|------------------|----------------|---------------------|---|--|
| Cr (mg/dl) | 1.4 \pm 0.37 | 2.0 \pm 0.48 | 1.4 \pm 0.33 | 1.4 \pm 0.42 |
| GFR (ml/min) | – | 33.6 \pm 10.17 | 47.9 \pm 15.36 | 51.3 \pm 19.11 |
| Urine ACR (mg/g) | – | 338.01 \pm 773.88 | 839.0 \pm 1603.19 | 309.0 \pm 676.60 |

Cr: creatinine; GFR: glomerular filtration rate; ACR: albumin/creatinine ratio.

[☆] Please cite this article as: Cobelo Casas CR, Millán Díaz B, González Tabarés L, Gómez Larrambe N, Cabezas González L, García Merino ML, et al. Insuficiencia renal asociada al uso de fibratos (n = 46). Nefrologia. 2017;37:216-217.

accelerated cell lysis² plus a decreased tubular secretion.³ In our series, neither liver enzymes nor creatine kinase were elevated. In conclusion, these cases represent patients in whom impaired kidney function was only attributable to fibrates. This is not a systematic review of all cases in which treatment with these drugs was started, and therefore the incidence of drug-associated kidney failure was not analysed. The relationship between kidney failure and the use of fibrates is clear; thus, kidney function should be closely monitored in patients that starts treatment with these types of drugs.

REFERENCES

1. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? *Nephrol Dial Transplant*. 2000;15:1993–9.
2. Salgueiro G, Beltrán LM, Torres RJ, Puig JG. Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia. *Nucleosides Nucleotides Nucleic Acids*. 2014;33:181–4.
3. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. *Nephron*. 2002;92:536–41.
4. Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. *Eur J Clin Invest*. 2013;43:522–31.
5. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. *Diabetes Care*. 2012;35:1008–14.
6. Attridge RL, Frei CR, Ryan L, Koeller J, Linn WD. Fenofibrate-associated nephrotoxicity: a review of current evidence. *Am J Health Syst Pharm*. 2013;70:1219–25.
7. McQuade CR, Griego J, Anderson J, Pai AB. Elevated serum creatinine levels associated with fenofibrate therapy. *Am J Health Syst Pharm*. 2008;65:138–41.

Carmen R. Cobelo Casas*, Beatriz Millán Díaz,
Lourdes González Tabarés, Nerea Gómez Larrambe,
Luís Cabezas González, María Luísa García Merino,
Jesús Calviño Varela

Servicio de Nefrología, Hospital Universitario Lucus Augusti, Lugo, Spain

*Corresponding author.

E-mail address: carmen.raquel.cobelo.casas@sergas.es
(C.R. Cobelo Casas).

2013-2514/© 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).
<http://dx.doi.org/10.1016/j.nefro.2017.04.006>

Libman-Sacks' endocarditis: A frequently unnoticed complication[☆]

Endocarditis de Libman-Sacks: una manifestación frecuentemente inadvertida

Dear Editor,

Here we describe the case of a 27-year-old female patient with a history of hypertension and cutaneous lupus, who was admitted for a kidney biopsy because she had proteinuria (2081 mg/g), microhaematuria (10–20 RBC/field) and mild functional impairment (Cr 1.3 mg/dl). The procedure was complicated with a severe perirenal haematoma, which required selective embolization and, subsequently, fever, which was attributed to the procedure and reabsorption of the haematoma; the microbiological tests were negative. The patient developed anaemia (Hb 8 g/dl) with normal WBC and platelets. Autoimmunity lab results were: ANA test was positive (1/160); the anti-DNA, positive (33 U/ml); and the ENA,

SSA, SSB, U1RNP, Sm and SCL70, negative. The lupus anticoagulant (2.3) and the IgG anticardiolipin antibodies (253 U/ml) were positive, with decreased C3 levels (70 mg/dl). The kidney biopsy showed a type III lupus nephritis. There were only 3 glomeruli (2 with an increased mesangial matrix and one with focal and segmental sclerosis/hyalinosis) with no “wire loop” lesions or glomerular crescent formations. Immunofluorescence showed deposits in the mesangium and the glomerular basement membrane of high intensity for IgG, C3 and C1Q, and mild/moderate intensity for IgA, IgM and C4.

The patient had cardiac murmur in the auscultation and the fever persisted, so an echocardiogram was performed that showed a bicuspid aortic valve with a vegetation s on the free edge of its 2 leaflets causing a severe insufficiency. Although it was unlikely that this lesion was caused by an infection, owing to the negative result on the blood cultures, a cardiac

[☆] Please cite this article as: Gómez-Larrambe N, González-Tabarés L, Millán B, Cobelo C, Armesto V, Pousa M, et al. Endocarditis de Libman-Sacks: una manifestación frecuentemente inadvertida. *Nefrología*. 2017;37:217–219.